News

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks
Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...
Devdiscourse36m
Merck's Bold $3.9 Billion Bid on SpringWorks: A Game-Changer in Rare Cancer Therapies
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...